---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-22-000029"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T15:37:55.906647+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho Q3 2022: revenue $783.8M (-21.8% combined const. currency); GAAP EPS $0.28; adjusts guidance up

## Summary
- Revenue $783.8M, +54% reported; supplemental combined revenue -21.8% constant currency; ex-COVID +3.0% (underlying +6.0%).
- GAAP diluted EPS $0.28 vs $5.08 prior year; adjusted diluted EPS $1.85 vs $4.01 (down 54%).
- GAAP operating margin 7% vs 55%; adjusted EBITDA margin 28.9% vs 42.5%.
- Full-year 2022 guidance raised; QuidelOrtho integration ahead of expectations.
- Base business growth driven by Point-of-Care and Donor Screening; strength in NA, LATAM, ASPAC offset by China/EMEA weakness.

## SEC filing metadata
- accession: 0001906324-22-000029
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632422000029/0001906324-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632422000029/qdel-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-22-000029
- JSON: https://secwatch.observer/filing/0001906324-22-000029.json
- Plain text: https://secwatch.observer/filing/0001906324-22-000029.txt

## Key facts
- Earnings Releases
  QuidelOrtho Corp reported third quarter ended October 2, 2022 results: revenue $783.8 million, EPS $0.28. Guidance raised.
  - Period: third quarter ended October 2, 2022
  - Revenue: $783.8 million
  - EPS: $0.28
  - Guidance: raised
  - Result: reported results
  source text: The Company reported total revenue for the third quarter of 2022 of $783.8 million, a 54% increase as reported, compared to $509.8 million for the third quarter of 2021. This was largely due to the consummation of the business combination that occurred on May 27, 2022 pursuant to a Business Combination Agreement entered into as of December 22, 2021, by and among Quidel Corporation (“Quidel”), Ortho Clinical Diagnostics Holdings plc (“Ortho”), QuidelOrtho, and the other parties thereto (the “Combinations”). GAAP diluted earnings per share (EPS) for the third quarter of 2022 decreased to $0.28, compared to $5.08 for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632422000029/0001906324-22-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.